AllianceBernstein
NMRA icon

AllianceBernstein’s Neumora Therapeutics NMRA Stock Holding History

AllianceBernstein’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-88,020
Closed -$88K – 3295
2025
Q1 		$88K Sell
88,020
-111,927
-56% -$192K ﹤0.01% 3081
2024
Q4 		$2.12M Sell
199,947
-22,930
-10% -$275K ﹤0.01% 1929
2024
Q3 		$2.94M Sell
222,877
-44,348
-17% -$517K ﹤0.01% 1766
2024
Q2 		$2.63M Buy
+267,225
New +$2.76M ﹤0.01% 1799

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

AllianceBernstein's NMRA Position: Q2 2025 in Review

AllianceBernstein sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 88,020 shares — an estimated $88K sold.

AllianceBernstein first reported a position in NMRA in Q2 2024 and held it in 4 quarters. The position peaked at $2.94M in Q3 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • AllianceBernstein reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 88,020 Neumora Therapeutics shares in Q2 2025, an estimated $88K.
  • AllianceBernstein first reported a position in Neumora Therapeutics in Q2 2024 and held it in 4 quarters.
  • AllianceBernstein's Neumora Therapeutics position peaked at $2.94M in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.